Journals / Türk Oftalmoloji Dergisi / 2021 / Cilt: 51 - Sayı: 1

Subretinal Coapplication of Tissue Plasminogen Activator and Bevacizumab with Concurrent Pneumatic Displacement for Submacular Hemorrhages Secondary to Neovascular Age-Related Macular Degeneration

Neovasküler Yaşa Bağlı Maküla Dejenerasyonu için Subretinal Doku Plazminojen Aktivatörü ve Bevacizumab Uygulaması Eşliğinde Pnömatik Yer Değiştirme Tedavisi

Pages
38–44
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mean preoperative SMH duration was significantly shorter in patients who achieved total resolution of the hemorrhage compared with the subtotal resolution group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate the functional and morphological outcomes of vitrectomy in combination with intravitreal 5% C3F8 tamponade and subretinal injections of tissue plasminogen activator (tPA) and anti-vascular endothelial growth factor (anti-VEGF) in patients with submacular hemorrhage (SMH) and to investigate the preoperative prognostic factors.
📊
Key Findings & Data:Materials and Methods: This retrospective study included 30 patients (16 women, 14 men) diagnosed with SMH secondary to neovascular age-related macular degeneration (AMD).
💡
Conclusion & Impact:The mean preoperative SMH duration was significantly shorter in patients who achieved total resolution of the hemorrhage compared with the subtotal resolution group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate the functional and morphological outcomes of vitrectomy in combination with intravitreal 5% C3F8 tamponade and subretinal injections of tissue plasminogen activator (tPA) and anti-vascular endothelial growth factor (anti-VEGF) in patients with submacular hemorrhage (SMH) and to investigate the preoperative prognostic factors. Materials and Methods: This retrospective study included 30 patients (16 women, 14 men) diagnosed with SMH secondary to neovascular age-related macular degeneration (AMD). Preoperative SMH thickness and area, ellipsoid zone integrity, and postoperative reduction in the amount of subfoveal blood on optical coherence tomography and fundus photographs were assessed. Furthermore, visual acuity (VA), hemorrhage duration, and the need for additional intravitreal anti-VEGF injections were recorded. Results: The patients’ mean age was 73.33±8.23 years. Mean VA improved from logMAR 2.11±0.84 at baseline to logMAR 1.32±0.91, 0.94±0.66, 1.13±0.84, and 1.00±0.70 at postoperative month 1, 2, 3, and 6, respectively. A significant negative correlation was found between hemorrhage duration and postoperative VA at month 2 (p=0.005), month 3 (p=0.019), and month 6 (p=0.012). The mean preoperative SMH duration was significantly shorter in patients who achieved total resolution of the hemorrhage compared with the subtotal resolution group (p

Özet

Amaç: Submaküler hemoraji (SMH) tanılı hastalarda, vitrektomi ile kombine subretinal doku plazminojen aktivatörü (tPA) ve antivasküler endotelyal büyüme faktörü (anti-VEGF) eşliğinde %5 C3F8 gaz tamponad cerrahisinin fonksiyonel ve morfolojik sonuçları yanı sıra preoperative prognostic faktörleri değerlendirmektir. Gereç ve Yöntem: Retrospektif çalışmamıza, yaşa bağlı maküla dejenerasyonuna (YBMD) sekonder SMH tanılı 30 hasta (16 kadın, 14 erkek) dahil edildi. Preoperatif SMH kalınlığı ve alanı, elipsoid zonun durumu yanı sıra postoperatif optik koherens tomografide subfoveal hemoraji miktarındaki azalma ve fundus fotoğrafları değerlendirildi. Ayrıca görme keskinliği (GK), hemorajinin süresi ve ek intravitreal anti-VEGF enjeksiyon ihtiyacı kaydedildi. Bulgular: Hastaların ortalama yaşı 73,33±8,23 idi. Ortalama GK logMAR 2,11±0,84’ten postoperatif 1. ayda logMAR 1,32±0,91, 2. ayda 0,94±0,66, 3. ayda 1,13±0,84 ve 6. ayda 1,00±0,70’e yükseldi. Hemorajinin süresi ile postoperatif 2. ay (p=0,005), 3. ay (p=0,019) ve 6. ay (p=0,012) GK’leri arasında anlamlı negatif korelasyon mevcuttu. Postoperatif total hemoraji rezolüsyonu elde edilen grupta SMH süresi subtotal rezolüsyon grubuna kıyasla anlamlı olarak kısaydı (p

🔖

Cite This Article

ÇINAR, E., KÜÇÜKERDÖNMEZ, C., YILMAZ, S., AVCI, R., YILDIZ, A. M., AKALP, F. D., AVCI, E. (2022). Subretinal Coapplication of Tissue Plasminogen Activator and Bevacizumab with Concurrent Pneumatic Displacement for Submacular Hemorrhages Secondary to Neovascular Age-Related Macular Degeneration. Türk Oftalmoloji Dergisi, Cilt: 51 - Sayı: 1, 38–44. https://ajindex.com/articles/637578

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. 1996;16:183-189
  2. Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol. 1997;42:195-213
  3. Toth CA, Morse LS, Hjelmeland LM, Landers MB. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109:723-729
  4. Kim JH, Chang YS, Kim JW, Kim CG, Yoo SJ, Cho HJ. Intravitreal antivascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization. Ophthalmology. 2014;121:926-935
  5. Cho HJ, Koh KM, Kim HS, Lee TG, Kim CG, Kim JW. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156:524-531
  6. Chang YS, Kim JH, Kim JW, Kim CG, Lee DW. Development of Submacular Hemorrhage in Neovascular Age-related Macular Degeneration: Influence on Visual Prognosis in a Clinical Setting. Korean J Ophthalmol. 2018;32:361- 368
  7. Bell JE, Shulman JP, Swan RJ, Teske MP, Bernstein PS. Intravitreal Versus Subretinal Tissue Plasminogen Activator Injection for Submacular Hemorrhage. Ophthalmic Surg Lasers Imaging Retina. 2017;48:26-32
  8. Kunavisarut P, Thithuan T, Patikulsila D, Choovuthayakorn J, Watanachai N, Chaikitmongkol V, Pathanapitoon K, Rothova A. Submacular Hemorrhage: Visual Outcomes and Prognostic Factors. Asia Pac J Ophthalmol (Phila). 2018;7:109-113
  9. Kumar A, Roy S, Bansal M, Tinwala S, Aron N, Temkar S, Pujari A. Modified Approach in Management of Submacular Hemorrhage Secondary to Wet AgeRelated Macular Degeneration. Asia Pac J Ophthalmol (Phila). 2016;5:143- 146
  10. Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal antiVEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol. 2012;96:708-713
  11. Shin JY, Lee JM, Byeon SH. Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage. Am J Ophthalmol. 2015;159:904-914
  12. Cubuk MÖ, Özdek S, Hasanreisoğlu B. Comparison of Pneumatic Displacement Method Anti VEGF and Tpa with Intravitreal Anti VEGF Therapy Alone in Fresh Limited Submacular Hemorrhage Cases. Ret-Vit. 2015;23:154-158
  13. Kapran Z, Ozkaya A, Uyar OM. Hemorrhagic Age-Related Macular Degeneration Managed With Vitrectomy